Last Updated : June 30, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Keytruda | pembrolizumab | recurrent, or metastatic cervical cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | Pembrolizumab | classical Hodgkin Lymphoma (cHL) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | Pembrolizumab | For locally advanced or metastatic urothelial carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | Pembrolizumab | MUC First line | Do not reimburse | Complete | ||
| Keytruda | Pembrolizumab | Squamous NSCLC | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | pembrolizumab | Gastric or gastroesophageal junction adenocarcinoma | Active | |||
| Keytruda | pembrolizumab | Biliary tract carcinoma | Active | |||
| Keytruda | Pembrolizumab | head and neck squamous cell carcinoma (HNSCC) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | pembrolizumab | Esophageal carcinoma, gastroesophageal junction adenocarcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | pembrolizumab | Advanced endometrial cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda and Lenvima | pembrolizumab and lenvatinib | Advanced endometrial cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda and Lenvima | pembrolizumab and lenvatinib | Advanced endometrial cancer | Withdrawn | |||
| Kimmtrak | tebentafusp | unresectable or metastatic uveal melanoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Kineret | anakinra | Still's disease | Withdrawn | |||
| Kisqali | Ribociclib | HR+, HER2- advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Kisqali | Ribociclib with Fulvestrant | +Fulvestrant for HR+, HER2- advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Kisqali | Ribociclib | Advanced or Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Kivexa | Abacavir/lamivudine | HIV infection | List in a similar manner to other drugs in class | Complete | ||
| Komboglyze | Saxagliptin + metformin | Diabetes Mellitus, Type 2 | Withdrawn | |||
| Komboglyze | Saxagliptin + metformin | Diabetes Mellitus, type 2 | List with criteria/condition | Complete | ||
| Korsuva | difelikefalin | Chronic kidney disease | Do not reimburse | Complete | ||
| Koselugo | selumetinib | Neurofibromatosis type 1 | Reimburse with clinical criteria and/or conditions | Complete | ||
| Kuvan | Sapropterin dihydrochloride | Phenylketonuria (PKU) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Kuvan | Sapropterin dihydrochloride | Phenylketonuria (PKU) | Do not list | Complete | ||
| Kuvan | Sapropterin dihydrochloride | Phenylketonuria | N/A | Complete |
Last Updated : June 30, 2024